Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04898309
Other study ID # CIR-HAE-II-III
Secondary ID #210, April 16,
Status Withdrawn
Phase Phase 2/Phase 3
First received
Last updated
Start date December 1, 2021
Est. completion date May 31, 2023

Study information

Verified date January 2022
Source AO GENERIUM
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in comparison with Berinert® in patients with hereditary angioedema


Description:

Hereditary angioedema is a rare, potentially life-threatening genetically determined disease associated with a deficiency or impairment of the functional activity of the C1-esterase inhibitor (C1-inhibitor). The main clinical manifestation of hereditary angioedema is recurrent subcutaneous or submucosal swelling of various localization. Most often, the development of the disease is based on a mutation in the SERPING1 gene. The prevalence of the disease in the world ranges from 1:10 000 to 1:150 000. GNR-038 is a recombinant C1 inhibitor (rhC1INH), which is a complete structural and functional analog of the plasma C1 inhibitor. Phase I study results showed convincing safety and tolerability evidence of GNR-038.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 31, 2023
Est. primary completion date May 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria 1. Men and women 18 years and older at the time of signing the Informed Consent Form. 2. Availability of written informed consent signed by the patient prior to the start of any procedures related to the study. 3. Confirmed diagnosis of HAE: - C4 level <50% of the lower limit of the range of normal laboratory values and one of the points below: - the C1INH level <50% of the lower limit of the range of normal laboratory values, OR - the level of C1INH within normal values, while the level of functional activity of C1INH is below 50% of the lower limit of the range of normal values. 4. Localization of the edema in the abdominal cavity, in the face area (lips, eyelids, subcutaneous tissue), limbs, trunk or in the area of the external genitals in the anamnesis. 5. =4 HAE attacks requiring treatment or causing significant functional impairment for 2 consecutive months in the 3-month period prior to Screening, properly documented in the medical records. 6. Patient's consent to adhere to reliable methods of contraception. Exclusion Criteria 1. Deviation of the C1q level below the normal limit. 2. B-cell lymphoproliferative diseases in the anamnesis or at the time of inclusion in clinical trial. 3. The presence of anti-C1INH autoantibodies. 4. Allergic reactions to the components of C1INH drugs or other blood components. 5. Glomerular filtration rate =59 ml/min/1.73 m2, calculated by the formula CKD-EPI Creatinine Equation (2009) (see Appendix). 6. The concentration of peripheral blood leukocytes >20*109/L. 7. Drug addiction, solvent abuse, alcoholism in the anamnesis or at the time of inclusion. 8. Participation in clinical trials of C1-esterase inhibitor drugs, blood transfusion and its components during the last 90 days prior to screening. 9. Participation in clinical trials of any other investigational drugs within the last 30 (thirty) days prior to screening. 10. Positive laboratory results for HIV and hepatitis B and C. 11. Pregnancy and lactation. 12. Diseases and conditions associated with thrombosis (myocardial infarction, transient ischemic attacks, deep and superficial vein thrombosis, and pulmonary embolism) less than 6 months before the start of the screening period, as well as an increased risk of arterial or venous thrombosis according to the study doctor's opinion. 13. Concomitant diseases and conditions that according to the study doctor's opinion put the patient's safety at risk when participating in the study, or that will affect the analysis of safety data if this disease/condition worsens during the study, including: - Mental illness; - Diseases of the immune and endocrine system that are not controlled by drug therapy (including decompensated diabetes mellitus and thyroid diseases); - Hematological diseases requiring chemotherapy; - Cancer or cancer in the past medical history, with the exception of cured basal cell carcinoma; - Decompensated liver diseases.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GNR-038, 50 ??/ kg
A single intravenous infusion of GNR-038, 50 ??/ kg less than 5 hours after the onset of edema.
GNR-038, 100 ??/ kg
A single intravenous infusion of GNR-038, 100 ??/ kg less than 5 hours after the onset of edema.
Berinert®, 20 ??/ kg
A single intravenous infusion of Berinert®, 20 ??/ kg less than 5 hours after the onset of edema.
Placebo
A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
GNR-038. The dose will be selected according to results of stage 1 clinical trial.
A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
Berinert®, 20 ??/ kg
A single intravenous infusion of Berinert®, 20 ??/ kg less than 5 hours after the onset of edema.

Locations

Country Name City State
Russian Federation Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology Moscow
Russian Federation Moscow City Clinical Hospital 52 Moscow
Russian Federation National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia Moscow
Russian Federation Rostov State Medical University Rostov-on-Don
Russian Federation LLC "Scientific Medical Center of General Therapy and Pharmacology" Stavropol'

Sponsors (1)

Lead Sponsor Collaborator
AO GENERIUM

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to symptoms relief onset of acute HAE attack within 24 hours after the end of the drug administration. A persistent decrease in the intensity of symptoms by 20 mm from the initial level on the visual analogue scale (VAS) will be regarded as a relief of symptoms of HAE. 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms 24 hours
Secondary Time to complete resolution of the symptoms of an acute HAE attack within 24 hours after the end of the study drug administration. Persistent absence of symptoms - 0 (zero) mm on the visual analogue scale (VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms 24 hours
Secondary Time to minimum manifestation onset of acute HAE attack symptoms after the completion of study drug administration. Persistent reduction in the intensity of symptoms below 20 (twenty) mm on the visual analogue scale(VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms 24 hours
Secondary The proportion of HAE exacerbation episodes that achieved symptom relief after 1 hour and 4 (four) hours after the end of study drug administration. 1 hour; 4 hours.
Secondary The rate of attacks with HAE current localization relapse or with the occurrence of a new acute attack of a different localization within 24 (twenty-four) hours after the study drug administration. 24 hours
Secondary The rate of attacks that required additional administration of emergency drugs (human C1-esterase inhibitor or icatibant). 24 hours
Secondary The rate of attacks that did not respond therapeutically to the study drug administration the lack of relief of HAE symptoms within 4 (four) hours after administration of the drug, the occurrence of a relapse of HAE of the current localization or the occurrence of a new acute attack of another localization within 24 (twenty-four) hours after drug administration, the need to use drugs that can weaken the symptoms of HAE (see drugs that are not recommended to treatment), within 24 (twenty-four) hours after drug administration. 4 hours; 24 hours
Secondary The intensity of acute HAE attack symptoms within 24 (twenty-four) hours after study drug administration. HAE intensity wiil be measured by visual analogue scale (VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms 24 hours
Secondary Frequency of adverse events. 14 days
Secondary Frequency of anti-drug antibody formation. 7 and 14 days
Secondary The level of anti-drug antibodies neutralizing activity. Laboratory measurement of antidrug antibody with neutralixing activity. 7 and 14 days
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06007677 - A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema Phase 2
Completed NCT00997204 - EASSI - Evaluation of the Safety of Self-Administration With Icatibant Phase 3
Completed NCT00438815 - Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Phase 3
Completed NCT00748202 - Berinert P Study of Subcutaneous Versus Intravenous Administration Phase 3
Completed NCT01426763 - A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase Phase 2
Terminated NCT04091113 - Hereditary Angioedema Kininogen Assay
Completed NCT00432510 - Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects Phase 1
Completed NCT03712228 - A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Phase 2
Active, not recruiting NCT05453968 - Berotralstat Treatment in Children With Hereditary Angioedema Phase 3
Recruiting NCT05505916 - An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) Phase 3
Recruiting NCT05511922 - PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial Phase 3
Not yet recruiting NCT02159430 - Hereditary AngioEdema, Neurobiology and Psychopathology N/A
Completed NCT02303626 - 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Phase 2/Phase 3
Completed NCT01984788 - Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE Phase 2
Completed NCT04888650 - Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema
Completed NCT02448264 - First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers Phase 1
Completed NCT05118958 - Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations Phase 1
Completed NCT06414252 - Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients
Active, not recruiting NCT04739059 - Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks Phase 3
Completed NCT02819102 - An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates Phase 1